RT Journal Article SR Electronic T1 Proteomic and Metabolomic Investigation of COVID-19 Patients with Elevated Serum Lactate Dehydrogenase JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2021.01.10.21249333 DO 10.1101/2021.01.10.21249333 A1 Haixi Yan A1 Xiao Liang A1 Juping Du A1 Zebao He A1 Yu Wang A1 Mengge Lyu A1 Liang Yue A1 Fangfei Zhang A1 Zhangzhi Xue A1 Luang Xu A1 Guan Ruan A1 Jun Li A1 Hongguo Zhu A1 Jiaqin Xu A1 Shiyong Chen A1 Chao Zhang A1 Dongqing Lv A1 Zongmei Lin A1 Bo Shen A1 Yi Zhu A1 Biyun Qian A1 Haixiao Chen A1 Tiannan Guo YR 2021 UL http://medrxiv.org/content/early/2021/01/11/2021.01.10.21249333.abstract AB Serum lactate dehydrogenase (LDH) has been established as a prognostic indicator given its differential expression in COVID-19 patients. However, the molecular mechanisms underneath remain poorly understood. In this study, 144 COVID-19 patients were enrolled to monitor the clinical and laboratory parameters over three weeks. Serum lactate dehydrogenase (LDH) was shown elevated in the COVID-19 patients on admission and declined during the convalescence period, and its ability to classify patient severity outperformed other clinical indicators. A threshold of 247 U/L serum LDH on admission was determined for severity prognosis. Next, we classified a subset of 14 patients into high- and low-risk groups based on serum LDH expression and compared their quantitative serum proteomic and metabolomic differences. The results found COVID-19 patients with high serum LDH exhibited differentially expressed blood coagulation and immune responses including acute inflammatory responses, platelet degranulation, complement cascade, as well as multiple different metabolic responses including lipid metabolism, protein ubiquitination and pyruvate fermentation. Specifically, activation of hypoxia responses was highlighted in patients with high LDH expressions. Taken together, our data showed that serum LDH levels is associated COVID-19 severity, and that elevated serum LDH might be consequences of hypoxia and tissue injuries induced by inflammation.Competing Interest StatementThe research group of T.G. is partly supported by Tencent, Thermo Fisher Scientific, SCIEX, and Pressure Biosciences Inc. T.G. is a shareholder of Westlake Omics Inc. G.R. is an employee of Westlake Omics Inc.Funding StatementThis work was supported by grants from National Key R&D Program of China (No. 2020YFE0202200), National Natural Science Foundation of China (81972492, 21904107, 81672086, 82072333), Zhejiang Provincial Natural Science Foundation for Distinguished Young Scholars (LR19C050001), Hangzhou Agriculture and Society Advancement Program (20190101A04), Zhejiang Provincial Natural Science Foundation of China (LQ19H100001). And Westlake Education Foundation, Tencent Foundation.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study is approved by the institutional medical ethics review board of Taizhou Hospital of Zhejiang Province and Westlake University.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data referred to in the manuscript are available and can be accessed online. http://www.iprox.org